Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-26 @ 4:01 PM
Ignite Modification Date: 2025-12-26 @ 4:01 PM
NCT ID: NCT06667206
Eligibility Criteria: 1. Trial Participants Children aged 6 months (23 - 28 weeks) at time of screening 2. Inclusion Criteria * Aged 6 months (23 - 28 weeks) at time of screening * Received all previous vaccines as per country Expanded Programme of Immunization (EPI) schedule, verified by child health card * Parents/caretakers willing to give informed consent for their and their children's participation and stay in the geographical area where the study would be conducted 3. Exclusion Criteria The participant may not enter the trial if any of the following apply: * Child not healthy enough to be vaccinated in the opinion of the investigator * Recent family history of measles infection (since birth) * Previous receipt of any measles vaccination * A family history of congenital or hereditary immunodeficiency other than HIV * Receipt of more than 1 week of immunosuppressant or immune modifying drugs e.g. high dose steroids. * Major congenital defects or serious chronic illness that in the opinion of the investigator are likely to modify immune responses or the ability to comply with the requirements of the study. * History of any neurological disorders or seizures * Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period * Other abnormalities or medical history that contraindicated measles vaccination
Healthy Volunteers: True
Sex: ALL
Minimum Age: 23 Weeks
Maximum Age: 28 Weeks
Study: NCT06667206
Study Brief:
Protocol Section: NCT06667206